Gaviscon is a non-prescription medication for the treatment of heartburn and GERD/(also known as GORD) (acid reflux). It is produced and distributed in the UK by Reckitt Benckiser and by GlaxoSmithKline in the US and Canada.
Gaviscon is taken to treat heartburn, similar to other antacids. Gaviscon is based on a mixture of the buffering agents and neutralizers calcium carbonate and sodium bicarbonate, the laxative magnesium carbonate and the gelling agents alginic acid and aluminium hydroxide. When taken by mouth the combination of the alginic acid and bicarbonate creates a barrier which prevents stomach acid from refluxing back up into the esophagus.
If reflux occurs, this protective barrier is the first to contact the esophageal mucosa, in lieu of gastric contents.
The Gaviscon infant variant for infants (≥ 1 years) and young children contains only the gelling agents sodium alginate and magnesium alginate. It is used to help stabilize the stomach contents and reduce reflux and regurgitation, but is not an antacid.
Gaviscon is taken to treat heartburn, similar to other antacids. Gaviscon is based on a mixture of the buffering agents and neutralizers calcium carbonate and sodium bicarbonate, the laxative magnesium carbonate and the gelling agents alginic acid and aluminium hydroxide. When taken by mouth the combination of the alginic acid and bicarbonate creates a barrier which prevents stomach acid from refluxing back up into the esophagus.
If reflux occurs, this protective barrier is the first to contact the esophageal mucosa, in lieu of gastric contents.
The Gaviscon infant variant for infants (≥ 1 years) and young children contains only the gelling agents sodium alginate and magnesium alginate. It is used to help stabilize the stomach contents and reduce reflux and regurgitation, but is not an antacid.
No comments:
Post a Comment